{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:42:49Z","timestamp":1793119369509,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"publisher","award":["06170506"],"award-info":[{"award-number":["06170506"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971706"],"award-info":[{"award-number":["81971706"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["202009185071"],"award-info":[{"award-number":["202009185071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ajp.2024.104172","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T18:43:29Z","timestamp":1722710609000},"page":"104172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects"],"prefix":"10.1016","volume":"100","author":[{"given":"Kenneth Chi-Yin","family":"WONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry Bok-Man","family":"LEUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict Ka-Wa","family":"LEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pak-Chung","family":"SHAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Sai-Yu","family":"LUI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7102-833X","authenticated-orcid":false,"given":"Hon-Cheong","family":"SO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ajp.2024.104172_bib1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jpsychires.2008.01.004","article-title":"Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia","volume":"42","author":"Ader","year":"2008","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/fam0000363","article-title":"Between- and within-subject associations of PTSD symptom clusters and marital functioning in military couples","volume":"32","author":"Allen","year":"2018","journal-title":"J. Fam. Psychol."},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Rev."},{"issue":"5","key":"10.1016\/j.ajp.2024.104172_bib4","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s12325-021-01689-8","article-title":"Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies","volume":"38","author":"Bernardo","year":"2021","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0b013e31828b28d5","article-title":"Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response","volume":"33","author":"Bishara","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12888-016-1121-1","article-title":"Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study","volume":"16","author":"Bressington","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/wps.21036","article-title":"Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials","volume":"22","author":"Burschinski","year":"2023","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.ajp.2024.104172_bib8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/03007995.2017.1419946","article-title":"Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia","volume":"34","author":"Castle","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.ajp.2024.104172_bib9","first-page":"2574","article-title":"Metabolic risk in depression and treatment with selective serotonin reuptake inhibitors: are the metabolic syndrome and an increase in cardiovascular risk unavoidable","volume":"2","author":"Ch\u00e1vez-Castillo","year":"2018","journal-title":"Vessel"},{"issue":"9","key":"10.1016\/j.ajp.2024.104172_bib10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1177\/0269881111430748","article-title":"Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study","volume":"26","author":"Chen","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.ajp.2024.104172_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/ajcn\/87.4.801","article-title":"Consequences of smoking for body weight, body fat distribution, and insulin resistance1","volume":"87","author":"Chiolero","year":"2008","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ajp.2024.104172_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","article-title":"Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine","volume":"189","author":"Chrzanowski","year":"2006","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib13","doi-asserted-by":"crossref","first-page":"26548","DOI":"10.4088\/JCP.MS19053BR3C","article-title":"Current treatment options and emerging agents for schizophrenia","volume":"81","author":"Correll","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2024.104172_bib14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1146\/annurev.psych.093008.100356","article-title":"The disaggregation of within-person and between-person effects in longitudinal models of change","volume":"62","author":"Curran","year":"2011","journal-title":"Annu. Rev. Psychol."},{"issue":"6","key":"10.1016\/j.ajp.2024.104172_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/schbul\/sbl037","article-title":"A case series: evaluation of the metabolic safety of aripiprazole","volume":"33","author":"De Hert","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2024.104172_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ajp.2019.08.010","article-title":"Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey","volume":"45","author":"Dong","year":"2019","journal-title":"Asian J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2024.104172_bib18","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/cpt.2083","article-title":"Randomized controlled trials versus real world evidence: neither magic nor myth","volume":"109","author":"Eichler","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/acps.12009","article-title":"Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia","volume":"127","author":"Fan","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"issue":"Suppl 8","key":"10.1016\/j.ajp.2024.104172_bib20","first-page":"100","article-title":"Metabolic alterations and drug interactions: the role of the association between antipsychotics\/mood stabilizers and cognitive deficits","volume":"34","author":"Fiorentino","year":"2022","journal-title":"Psychiatr. Danub."},{"issue":"8","key":"10.1016\/j.ajp.2024.104172_bib21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.ajp.2024.104172_bib22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1017\/S1461145712001241","article-title":"Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial","volume":"16","author":"Fleischhacker","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.ajp.2024.104172_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.ajp.2024.104172_bib24","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ajp.2024.104172_bib25","unstructured":"Hamaker, E.L., Why researchers should think\" within-person\": A paradigmatic rationale. 2012."},{"issue":"2","key":"10.1016\/j.ajp.2024.104172_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","article-title":"Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients","volume":"29","author":"Henderson","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/obr.12358","article-title":"Why are there race\/ethnic differences in adult body mass index\u2013adiposity relationships? A quantitative critical review","volume":"17","author":"Heymsfield","year":"2016","journal-title":"Obes. Rev."},{"issue":"9","key":"10.1016\/j.ajp.2024.104172_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","author":"Hirsch","year":"2017","journal-title":"Drug Saf."},{"issue":"10202","key":"10.1016\/j.ajp.2024.104172_bib29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ajp.2024.104172_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1365-2125.2011.04023.x","article-title":"Effect of nicotine on cytochrome P450 1A2 activity","volume":"72","author":"Hukkanen","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40471-013-0004-y","article-title":"Confounding by Indication and Related Concepts","volume":"1","author":"Joseph","year":"2014","journal-title":"Curr. Epidemiol. Rep."},{"issue":"7","key":"10.1016\/j.ajp.2024.104172_bib32","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.psyneuen.2011.01.005","article-title":"Citalopram improves metabolic risk factors among high hostile adults: results of a placebo-controlled intervention","volume":"36","author":"Kamarck","year":"2011","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.ajp.2024.104172_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2024.104172_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","article-title":"Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia","volume":"32","author":"Kim","year":"2009","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2024.104172_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/YCO.0b013e32835035ca","article-title":"Life expectancy and cardiovascular mortality in persons with schizophrenia","volume":"25","author":"Laursen","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.psychres.2010.04.050","article-title":"Metabolic profile of first and second generation antipsychotics among Chinese patients","volume":"185","author":"Lee","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ajp.2024.104172_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2017.11.010","article-title":"T4 and waist:hip ratio as biomarkers of antipsychotic-induced weight gain in Han Chinese inpatients with schizophrenia","volume":"88","author":"Li","year":"2018","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"10.1016\/j.ajp.2024.104172_bib38","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/jpm12091362","article-title":"Racial\/ethnic differences in the pharmacokinetics of antipsychotics: focusing on East Asians","volume":"12","author":"Lin","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ajp.2024.104172_bib39","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1007\/s11434-011-4734-2","article-title":"A family study of endophenotypes for psychosis within an early intervention programme in Hong Kong: Rationale and preliminary findings","volume":"56","author":"Lui","year":"2011","journal-title":"Chin. Sci. Bull."},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4088\/JCP.08m04267","article-title":"The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia","volume":"70","author":"Meyer","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2024.104172_bib41","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib42","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1186\/s12889-024-18734-0","article-title":"Association between lipid profiles and cigarette smoke among adults in the Persian cohort (Shahedieh) study","volume":"24","author":"Momayyezi","year":"2024","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.ajp.2024.104172_bib43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4088\/JCP.18m12717","article-title":"Early stabilization of weight changes following treatment with olanzapine, risperidone, and aripiprazole: a 12-month naturalistic study of first episode psychosis","volume":"80","author":"Mustafa","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.ajp.2024.104172_bib44","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1440-1819.1981.tb00203.x","article-title":"Differential sensitivity to the effects of psychotropic drugs: psychotics vs normals; Asian vs Western populations","volume":"35","author":"Okuma","year":"1981","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ajp.2024.104172_bib46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/978-3-030-62059-2_402","article-title":"Lipid metabolism disturbances during antipsychotic treatment for schizophrenia","author":"Ono","year":"2022","journal-title":"NeuroPsychopharmacotherapy"},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ajp.2024.104172_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(23)00262-6","article-title":"Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development","author":"Pillinger","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neulet.2005.10.096","article-title":"Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells","volume":"395","author":"Raeder","year":"2006","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ajp.2024.104172_bib50","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.genhosppsych.2016.09.005","article-title":"Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia","volume":"43","author":"Rekhi","year":"2016","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.ajp.2024.104172_bib51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40501-017-0131-z","article-title":"Pharmacological approaches to minimizing cardiometabolic side effects of mood stabilizing medications","volume":"4","author":"Rosenblat","year":"2017","journal-title":"Curr. Treat. Options Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2024.104172_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00406-018-0884-4","article-title":"Obsessive\u2013compulsive symptoms in psychotic disorders: longitudinal associations of symptom clusters on between- and within-subject levels","volume":"269","author":"Schirmbeck","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.ajp.2024.104172_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.schres.2019.12.032","article-title":"Stressful experiences affect the course of co-occurring obsessive-compulsive and psychotic symptoms: a focus on within-subject processes","volume":"216","author":"Schirmbeck","year":"2020","journal-title":"Schizophr. Res."},{"issue":"9","key":"10.1016\/j.ajp.2024.104172_bib54","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.2011.10111609","article-title":"A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)","volume":"168","author":"Stroup","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/WNF.0b013e31817c6b06","article-title":"Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial","volume":"32","author":"Takahashi","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ajp.2024.104172_bib56","series-title":"The Maudsley prescribing guidelines in psychiatry","author":"Taylor","year":"2021"},{"issue":"6_suppl","key":"10.1016\/j.ajp.2024.104172_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1359786806071243","article-title":"Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses","volume":"20","author":"Turner","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2024.104172_bib58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jclinepi.2018.11.021","article-title":"Hybrid models were found to be very elegant to disentangle longitudinal within- and between-subject relationships","volume":"107","author":"Twisk","year":"2019","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2024.104172_bib60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.9740\/mhc.2022.10.270","article-title":"An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use","volume":"12","author":"VandenBerg","year":"2022","journal-title":"Ment. Health Clin."},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib61","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-017-4763-x","article-title":"Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-na\u00efve patients with a first-episode of non-affective psychosis","volume":"235","author":"V\u00e1zquez-Bourgon","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ajp.2024.104172_bib62","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/NDT.S80925","article-title":"Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study","author":"Wani","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ajp.2024.104172_bib63","first-page":"1361","article-title":"The comparison of glucose and lipid metabolism parameters in drug-naive, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia","volume":"10","author":"Wu","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.ajp.2024.104172_bib64","doi-asserted-by":"crossref","first-page":"6988","DOI":"10.1038\/s41467-023-42423-y","article-title":"Development and validation of an age-sex-ethnicity-specific metabolic syndrome score in the Chinese adults","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ajp.2024.104172_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.797183","article-title":"The racial disparities in the epidemic of metabolic syndrome with increased age: a study from 28,049 Chinese and American Adults","volume":"9","author":"Zhang","year":"2022","journal-title":"Front. Public Health"},{"issue":"3","key":"10.1016\/j.ajp.2024.104172_bib66","doi-asserted-by":"crossref","first-page":"16879","DOI":"10.4088\/JCP.19m12785","article-title":"Metabolic effects of 7 antipsychotics on patients with schizophrenia: a short-term, randomized, open-label, multicenter, pharmacologic trial","volume":"81","author":"Zhang","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2024.104172_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103594","article-title":"Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China","volume":"84","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatry"}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187620182400265X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187620182400265X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T02:13:59Z","timestamp":1726366439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187620182400265X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":67,"alternative-id":["S187620182400265X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104172","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.04.24303695","asserted-by":"object"}]},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104172"}}